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The competitive pressure from non-vaccine serotypes may have helped
pneumococcal conjugate vaccines (PCVs) to limit vaccine-type (VT) serotype
prevalence. We aimed to investigate if, consequently, the indirect protection
of vaccines targeting most pneumococcal serotypes could fall short of the pro-
found effects of current formulations.We compared three previously described
pneumococcal models harmonized to simulate 20 serotypes with a combined
pre-vaccination prevalence in children younger than 5-years-old of 40%. We
simulated vaccines of increasing valency by adding serotypes in order of
their competitiveness and explored their ability to reduce VT carriage by 95%
within 10 years after introduction. All models predicted that additional valency
will reduce indirect vaccine effects and hence the overall vaccine impact on
carriage both in children and adults. Consequently, theminimal effective cover-
age (efficacy against carriagevaccine coverage) needed to eliminate VT
carriage increased with increasing valency. One model predicted this effect
to be modest, while the other two predicted that high-valency vaccines may
struggle to eliminate VT pneumococci unless vaccine efficacy against carriage
can be substantially improved. Similar results were obtained when settings
of higher transmission intensity and different PCV formulationswere explored.
Failure to eliminate carriage as a result of increased valency could lead to over-
all decreased impact of vaccination if the disease burden caused by the added
serotypes is low. Hence, a comparison of vaccine formulations of varying
valency, and pan-valent formulations in particular, should consider the
invasiveness of targeted serotypes, as well as efficacy against carriage.1. Background
Streptococcus pneumoniae is a bacterium that commonly colonizes the nasopharynx,
in particular among children. There are over 90 pneumococcal serotypes that differ
in their polysaccharide capsule. The capsule has been found to be the major deter-
minant of a serotype’s epidemiology as it effects the host’s ability to clear the
pneumococcus and the probability that colonization leads to pneumococcal dis-
ease [1,2]. In comparison to colonization, pneumococcal disease is rare but can
include otitis media, pneumonia, bacteraemia or meningitis and aggregates to a
major public health burden [3]. In 2000, the first pneumococcal conjugate vaccine
(PCV), which provided protection against seven of the most pathogenic pneumo-
coccal capsular serotypes, was licensed and recommended for immunization of
infants in the USA [4]. Subsequently, 10- and 13-valent formulations have been
licensed and are now being used to prevent pneumococcal disease in more than
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2130 countries worldwide [5–14]. The incidence of carriage and
disease associated with vaccine-type (VT) serotypes declined in
vaccinated children, and also in unvaccinated children and
adults, after PCVs were introduced into national immunization
programmes [15]. However, the overall prevalence of
pneumococcal carriage remained approximately constant as
non-vaccine-type (NVT) serotypes, i.e. serotypes not targeted
by the vaccine, filled the ecological niche [16]. The increaseddis-
ease from these serotypes has partially offset the benefit of
pneumococcal vaccination [15,17,18]. As a result, pneumococ-
cal vaccines that target more or all serotypes are being
developed [19].
Previous work has suggested that the competition between
VT and NVT serotypes plays an important role in the herd
protection observed in the post-PCV era [20–22]. In particular,
by reducing acquisition of VT carriage, PCVs give NVTs a
competitive advantage over VTs in the nasopharynx. Thus, in
vaccinated populations, the presence of NVT in vaccinated
hosts provides additional competitive pressure, which com-
bines with the immune protection afforded by the vaccine, to
suppress VT colonization. Moreover, at the population level,
there is competition between VT and NVT in non-vaccinated
hosts, and also the spread of VT is likely inhibited by compe-
tition from NVT in non-vaccinated people. In each of these
cases, themechanisms of competitionmight includedirect com-
petition in the nasopharynx [23], induction of innate immune
effectors by NVT that also inhibit VT [24] and induction of
forms of acquired immunity that also inhibit VT, such as Th17-
based and antibody-based immunity to conserved antigens
[25–27]. For high-valency pneumococcal vaccines, including
those that target proteins common to most pneumococci [19],
this hypothesis implies that levels of indirect protection in
unvaccinated individuals could fall short of the profoundeffects
that have been observed with the routine use of conjugate vac-
cines. This would result from effectively losing the benefit of
NVT competition and applies even to vaccines with similar
vaccine efficacy against pneumococcal carriage and disease.
In this paper, we explore three previously developed
dynamic modelling approaches for pneumococcal ecology as
to whether they predict a similar qualitative contribution of
NVT competition to the indirect effects of pneumococcal vacci-
nation. We harmonized key model parameters that govern
vaccine efficacyandpneumococcal epidemiology in the absence
of vaccination and explored various vaccine scenarios to better
understand the role of competition in providing protection.2. Material and methods
2.1. Models
The model by Bottomley et al. [21] (M_B) is a deterministic model
that represents the pre-PCV steady state of pneumococcal infections
in the Gambia. It was used to predict the impact of introduction of
PCV13 into the childhood vaccination programme and is fitted to
local longitudinal pre-vaccination carriage data. Serotypes are
grouped into low, medium or high transmissibility (the probability
of onward transmission, given a potentially infectious contact) and
high, medium or low clearance rate (the reciprocal of the duration
of carriage). Serotypes within the same group share the same prop-
erties. Pneumococcal carriers are assumed to gain partial immunity
against acquisition of new serotypes during the episode of carriage,
which represents the mechanism of serotype competition. A pro-
portion of clearances leads to lifelong immunity against the
cleared serotype,which balances competitive advantages to sustainserotype diversity. The default model parametrization is the same
as reported in the original manuscript.
The model by Cobey & Lipsitch [28] (M_CL) is an individual-
based model that represents a generic high-income setting.
Serotypes differed by their intrinsic duration of carriage and their
in vivo competitive ability. Pneumococcal carriers are assumed to
gain partial protection, quantified by the competitive ability of
the resident type, against acquisition of additional serotypes
during the episode of carriage. This represents the mechanism of
competition. Following clearance, the host’s susceptibility to any
subsequent homologous acquisition as well as the duration of
any subsequent carriage episode is reduced. The strength
of acquired immunity that reduces carriage duration was fitted to
observations from a longitudinal carriage study in infants [29].
Serotype-specific immunity accentuates within-serotype compe-
tition, thus providing balancing selection on serotypes, and
acquired immunity independent of capsule reduces fitness differ-
ences. The simulations presented in this work rely on the default
model parametrization. This includes homogeneous mixing, the
default rate of acquisition of capsular immunity (s ¼ 0.3) and
the default rate of acquisition of non-specific immunity assuming
nonlinear reduction in carriage duration (e ¼ 0.25).
The model by Flasche et al. [20] (M_F) is an individual-based
model that generalizes the most commonly used deterministic
pneumococcal model [22,30,31]. It represents a generic high-
income country setting. Serotypes differ by their intrinsic duration
of carriage. Duration of carriage and susceptibility to acquisition
decline with age but are exposure-independent. The acquisi-
tion of a pneumococcus triggers both a transient homologous
immune response, which represents serotype competition, and a
transient heterologous immune response, which represents the
mechanism to ensure serotype coexistence. Both immune responses
are assumed to prevent additional acquisition of respective sero-
types. Unless mentioned otherwise, the simulations presented in
this work rely on the default model parametrization, i.e. the dur-
ation of specific and non-specific immunity was nine and 18
weeks, respectively.
While there was no formal model selection process, we
included dynamic models that simulate serotype competition,
that have been used to assess vaccine impact and that span most
of the range of alternative assumptions on serotype competition
and natural immunity. In particular, M_F is a generalization of
the most commonly used compartmental modelling approaches
and therefore those approaches were not included [30–38]. An
overview of the different modelling approaches in this study is
shown in table 1. The main differences between models, in regard
to this work, are the assumptions on acquired immunity and the
resulting mechanisms for competition and serotype coexistence.
2.2. Analyses
We harmonized models to simulate 20 artificial serotypes with a
combined pre-vaccination prevalence in children younger than
5 years old of 40%, approximating a high-income setting with
moderate transmission, or 70%, approximating a low-income set-
ting with high transmission intensity. In M_B, serotypes were
evenly distributed between the three classes, i.e. seven, seven
and six serotypes of low, mid and high transmission intensity,
respectively. For each model, parameters governing transmission
intensity were scaled to achieve the desired prevalence. In M_F,
changing the transmission intensity alone was insufficient to
achieve the targeted 70% prevalence as the acquired immunity
on infection was too strong and long lasting to permit such high
levels of carriage prevalence [20]. Hence, once the effects of increas-
ing the transmission intensity saturated, it was kept constant and
the duration of specific and non-specific immunity were sub-
sequently decreased to six and 12 weeks, respectively, to achieve
the targeted prevalence. As M_B was not age structured, we split
all compartments into a less than 5 year old and a 5 years and
Table 1. Summary of the main features of each model of pneumococcal transmission.
Bottomley et al. [21] Cobey & Lipsitch [28] Flasche et al. [17,20,37,39]
model type compartmental individual-based individual-based
demographics Gambia high-income country high-income country
mixing patterns homogeneous homogeneous age-assortative
natural immunity as
a result of
infection
non-speciﬁc: transient immunity
for the duration of infection
anticapsular: chance to develop
permanent homologous
immunity
non-speciﬁc: permanent increase in clearance
rate, transient reduction in acquisition rate
for the duration of infection
anticapsular: permanent reduction in
susceptibility to homologous infection
non-speciﬁc: transient immunity to
heterologous infection
anticapsular: additional transient
immunity to homologous infection
other: exposure-independent
reduction of susceptibility and
carriage duration with age
vaccine-induced
immunity
like anticapsular natural
immunity but higher chance
for protection
like anticapsular natural immunity but stronger
protection
like anticapsular natural immunity
but longer protection
Table 2. PCV formulations and the ranks of each serotype in terms of its
global prevalence according to a review on the global distribution of
paediatric pneumococcal carriage.
serotypes (rank)
PCV7 4 (18), 6B (2), 9 V (6), 14 (5), 18C (11), 19F (1), 23F (3)
PCV10 þ1 (31), 5 (38), 7F (32)
PCV13 þ3 (9), 6A (4), 19A (7)
PCV15 þ22F (27), 33F (24)
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3older compartment retaining all original parameters and constant
rate of transition between the strata such that the mean time spent
in the less than five stratum was 5 years. To minimize the effects
of stochasticity, M_CL was run 10 times and mean values are pre-
sented. Stochastic variability on presented outcomeswas too small
to visualize in the figures so it was omitted. The Simpson index
was calculated as a measure of serotype diversity [40].
We explored two vaccines with alternative compositions.
Firstly, we compared generic vaccines of increasing valency
where serotypes are included in order of their competitiveness.
Modelled serotype M1 is the strongest competitor, indicated in
all models by the highest prevalence in the pre-vaccine era, and
M20 the lowest. Note that the serotype names do not correspond
to the numbering conventionally used for pneumococcal sero-
types. Secondly, to approximate PCV7, PCV10, PCV13 and
PCV15, we modelled inclusion of serotypes into the vaccine in
respect of their observed paediatric prevalence rank in global car-
riage (private communication with Olivier Le Polain 2017). For
example, PCV7 targets serotypes 4, 6B, 9 V, 14, 18C, 19F and 23F
which are the 18th, 2nd, 6th, 5th, 11th, 1st and 3rd most prevalent
serotypes globally. Hence, the PCV7-like vaccine in this work tar-
gets model serotypesM1,M2,M3,M5,M6,M11 andM18 (table 2).
Serotypes of a lower rank than 20 were not included because the
models only consisted of 20 serotypes. We did not consider the
23-valent pneumococcal polysaccharide vaccine as it is not
licensed for use in children and does not confer protection against
pneumococcal carriage.
M_B and M_F assume that immunity, including vaccine-
induced immunity, acts as all-or-nothing immunity (individuals
are either immune or not) while the Cobey and Lipsitch model
assumes immunity is leaky (individuals gain partial immunity).The models were run to predict the impact of vaccination against
each targeted serotype [41]. This assumed 100% vaccine coverage
(the proportion of the target population who are immunized)
and 55% vaccine efficacy (the reduction in the rate of colonization
of a vaccinated compared with an unvaccinated person). Also,
the models were run to predict the effective coverage needed
to achieve elimination of VT carriage. We defined effective cover-
age as vaccine efficacy times vaccine coverage. In the two models
that assume all-or-nothing vaccine protection, this is equivalent
to the fraction of the population that is protected by vaccination,
in the M_CL, we assumed 100% population coverage and vary-
ing vaccine efficacy. We defined elimination of VT carriage as a
reduction in VT carriers of 95% or more. The impact of vacci-
nation is measured as either the percentage reduction in the
number of VT carriers or alternatively with any serotype, in
year 10 after the start of vaccination if compared to the year
before vaccination (steady state). We choose to report only the
vaccine impact after 10 years of PCV use as for this work
we were only interested in potential qualitative differences in
predictions in the mid to long term after vaccine introduction.3. Results
Models differed in the proportion of children among the simu-
lated population. M_B assumed an age distribution based on
the Gambia and hence that children younger than 5 years old
make up 20% of the total population. In both other models
that represent high-income countries, the corresponding pro-
portion was 5% (figure 1). Pneumococcal carriage prevalence
was almost evenly distributed across serotypes in M_F and
dominated by fewer serotypes in M_CL. The Simpson indices
in children were 0.871, 0.845 and 0.885 in the moderate trans-
mission scenario for M_B, M_CL and M_F and 0.925, 0.862
and 0.927 in the high transmission scenario. In individuals
older than 5 years, the predicted prevalence varied between
the models (in children less than 5 years, it was fixed at 40%
or 70%; figure 1). Carriage prevalence decreases with age
except for M_B which was originally designed to be age-
independent and hence uses the same parameters for both
age groups.
In the moderate transmission scenario, the vaccine impact
against VT carriage 10 years after the start of vaccination of a
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Figure 1. Model demographics and serotypes distribution before the introduction of vaccination. (a) The age distribution of the model populations. (b) A stacked
barplot to illustrate the predicted serotype distributions (stacked prevalence of serotype-specific carriage episodes scaled to the overall carriage prevalence) in
children and the rest of the population in low and high transmission settings. The grey line indicates the targeted prevalence. (Online version in colour.)
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4vaccine with 55% effective coverage decreased with increasing
vaccine valency in all three models (figure 2; electronic sup-
plementary material, figure S2). The effect of including more
VTs was least visible in M_CL where only inclusion of almost
all serotypes (15 or more) reduced the impact on VT carriage
to allow VT circulation. The M_B predicted the steepest
decrease in vaccine impact on VT prevalence as a result of
inclusion of highly and moderately competitive serotypes.
However, further inclusion of weakly competitive serotypes,
which were hardly carried in this scenario, did not change the
impact of vaccination. Similar dynamics were observed for
older individuals and the high transmission scenario; however,
M_F predicted a small initial increase in vaccine impact on VT
carriage before the impact decreased for higher valencies.
The impact of vaccination on all serotype carriagemeasured
10 years after the start of vaccination with a vaccine with 55%
effective coverage generally increased with increasing valency.However, for the high transmission scenario, M_CL predicted
an increase in overall pneumococcal carriage through the
inclusion of almost all serotypes into the vaccine formulation.
Only for valencies of 19 and higher, M_CL predicted a
reduction in all serotype carriage prevalence.
The PCV7-like and PCV10-like as well as the PCV13-like
and PCV15-like vaccines were indistinguishable. This is
because the global prevalence ranks of the respectively added
serotypes were larger than the number of serotypes considered
in this analysis and hence omitted. All three models predicted
that the impact of vaccination against paediatric VT carriage
is similar (less than 5% difference) across the PCV-like formu-
lation (figure 3). However, differences in vaccine impact on
carriagewith any serotypeweremore pronounced but followed
the dynamics of the generic vaccine; i.e. inclusion of more sero-
types further reduced carriage prevalence, except in M_CL in
the high transmission scenario.
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6Consistent with the effect of increasing valency on vaccine
impact, increasing the valency of the generic vaccine formu-
lation was predicted to increase the effective coverage needed
to eliminate VT carriage in both children and older indivi-
duals and in both moderate and high transmission intensity
settings (figure 4). In all three models VT elimination in the
general population required less than 10% additional effective
coverage compared with elimination of VT carriage among
children. In contrast with the other models, M_CL predicted
that addition of up to half of all serotypes into the generic
vaccine formulation would not have a profound effect on the
effective coverage needed for elimination of VT carriage.
Only inclusion of at least 10 serotypes or 15 serotypes in the
moderate and high transmission scenario, respectively,
would see the need to increase the effective coverage. Elimin-
ation of pneumococci using a pan-valent vaccine was
impossible in M_F and also for the high transmission scenario
in M_B.
For PCV-like vaccines, a similar qualitative behaviour to
the generic vaccine formulations was predicted. The three
models predicted that the effective coverage needed to elim-
inate VT carriage in the population increases by 12, 2 and
11%, respectively, for the moderate transmission intensity set-
ting if a PCV13 or 15-like vaccine was used instead of a PCV7
or 10-like vaccine. In the high transmission intensity setting,
elimination of VT carriage for the two modelled vaccine
formulations was impossible in M_F, required effective cover-
age larger than 88 and 97% in M_B and required effective
coverage of 34 and 37% in M_CL.4. Discussion
PCVs have substantially reduced the burden of pneumococcal
disease worldwide. However, through replacement with sero-
types not targeted by the vaccines, a sizeable burden remains
and has led to ongoing development of vaccines with higher
valency. Using qualitative results across three pneumococcal
models that span a variety of assumptions on the acquisition
of pneumococcal immunity and serotype competition, we
here show that serotype competition from NVTs aids VT elim-
ination. Accordingly, we show that targeting an increasing
number of serotypes increases the requirements on vaccineefficacy and/or vaccine coverage to achieve elimination of
VT carriage. We predict that the relatively small differences
in the number of serotypes targeted by current PCV formu-
lations are unlikely to be substantial enough to lead to
measurable differences in the ease of VTelimination. However,
vaccines that target almost all serotypes may allow continued
circulation of the most competitive serotypes, even if the vac-
cine was given at high coverage and if the vaccine efficacy
against carriage was improved over the efficacy of PCVs.
Given the qualitative nature of this comparison, we have
only assessed the impact of vaccine valency on the potential
of elimination of pneumococcal carriage. The implications
of the results for the disease impact of a switch from
current PCV formulations to a pan-valent vaccine are complex.
Increasing vaccine valency could lead to a net increase in pneu-
mococcal disease burden if two conditions are met: first, the
highly competitive serotypes are controlled only through avac-
cine with limited valency and are also highly pathogenic and
second, the types not targeted by the formulation with limited
valency rarely cause disease. In this case, the small disease
benefit of controlling more serotypes could be outweighed by
the increased circulation of the serotypes in the limited-valency
vaccine. The expansion of PCV formulations to incorporate
additional serotypes that are responsible for significant
amounts of disease has tended to emphasize highly invasive
serotypes, thereby minimizing the potential problem we high-
light for expansions of the valency of PCVs. Also, a method for
selecting serotypes has been proposed thatwould furthermini-
mize the issue of serotype replacement for higher-valency
PCVs [42].
In vaccinated persons, these unintended effects might be
fully or partially offset through the additional direct vaccine
protection against disease, given that PCV formulations
thus far have provided greater than 80% protection against
disease, with lower efficacy against carriage [41,43–45].
This implies that unintended effects of increased valency of
vaccines might be of greatest concern, and thus most deser-
ving of surveillance, in age groups within a population that
has not been vaccinated, such as healthy adults. We empha-
size that the model-comparison exercise here was designed
to assess general trends in the behaviours of the models,
rather than to predict specifically how a higher-valency vac-
cine would act in a particular population. Setting-specific
rsif.royalsocietypublishing.org
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7model parametrization is required to allow quantification
of the differential impact of vaccine of varying valency on
pneumococcal disease.
The principal outcome of this study is that all three
models consistently predicted the same qualitative behaviour
in response to increasing vaccine valency.We find that serotype
competition aids VT elimination and hence that increasing the
valency of pneumococcal vaccines increases the herd immunity
threshold. For each model, this result was consistent across
moderate and high transmission settings and for different
vaccine formulations (figures 2 and 3). The finding was also
consistent when we explored the impact of a vaccine with a
given efficacy and when we estimated the effective coverage
needed for VT elimination (figures 2 and 4). Similar to other
model-comparison studies that assessed vaccine impact, we
did not systematically test the sensitivity of eachmodel’s predic-
tion to its ecological assumptions but rather used the differences
in assumptions between models to conclude whether our find-
ings are robust [39,46]. In particular, our principal qualitative
results were consistent across models despite different model
assumptions on the underlying demography, the mechanisms
of between serotype competition and the immune memory
induced by both pneumococcal infection and vaccination.
While none of the three models has been fitted to post-
vaccination data, and only M_B was fitted to pre-vaccine
data, they all replicate the observed epidemiology in that they
predict that a PCV-like vaccine will eliminate most VT carriage
within a few years after introduction and that NVTs will
almost completely take over the ecological niche so that overall
pneumococcal carriage prevalence remains unchanged.
Wemade the simplifying assumption that serotype-specific
direct vaccine effects are the same across vaccines and targeted
serotypes and that they follow those of current PCV formu-
lations; i.e. an approximately 55% efficacy against carriage
acquisition of any targeted serotype [41]. However, because
of the complexities involved in the conjugation procedure of
PCVs, it is unlikely that using current techniques, PCVs will
be able to target more than 20 of the over 90 pneumococcal
serotypes [47]. Vaccines that target common proteins rather
than specific capsules, on the other hand, may prevent pneu-
mococcal disease by different mechanisms, e.g. enhanced
IL-17A-mediated nasopharyngeal clearance rather than pre-
vention of acquisition [48]. While inference of the differential
population impact of specific pneumococcal vaccines would
require a more precise parametrization including the focus
on a specific setting, the qualitative results of this work are
likely to similarly apply.
In a few instances, the models predicted changes to
pneumococcal ecology following vaccination that seem
counterintuitive at first. In the high transmission scenario,
M_CL predicted that overall paediatric carriage prevalence
would stay relatively constant (less than 5% change) for vac-
cines that included up to eight of the most competitive
serotypes. However, if more serotypes were targeted by the
vaccine, then carriage prevalence increased by up to 40%.
Only if at least 19 serotypes were targeted, carriage prevalence
was found to decrease (figure 2). This finding is unique to this
model because of its inclusion of a gradient in type-specific
ability to prevent additional acquisition: carriers of highly com-
petitive serotypes are more protected against acquisition of
further serotypes. By protecting against the most competitive
serotypes through vaccination, the remaining serotypes are
under less pressure from competition to a point where theyact almost independently. For vaccines that target between 9
and 18 of all serotypes in the high transmission setting, the
prevalence of untargeted serotype in the virtual absence of
competition then adds up to exceed the overall prevalence
before vaccination (electronic supplementary material,
figure S1). Furthermore, in M_CL, the impact of vaccination
with low valency vaccines is similar in both transmission
settings but slightly higher for moderate to high-valency
vaccines in high transmission settings than in moderate trans-
mission settings. By contrast, most models including M_B and
M_F predict that transmission intensity and the herd immunity
threshold are always positively correlated [49]. In M_CL, that
same effect is evident only for vaccines that target all serotypes.
For vaccines that target most pneumococci, this model predicts
a substantial increase in overall pneumococcal prevalence in
high transmission scenarios. The enhanced presence of NVTs
in this scenario helps to control VT circulation slightly better
than vaccination in a moderate transmission scenario with
less transmissible VTs but also lower NVT carriage prevalence
and less competition as a result. When assuming 55% effective
coverage in the high transmission scenario, M_F predicted
that increasing the valency to up to 15 serotypes leads to a
small increase in vaccine impact on VT carriage. This is
qualitatively different from all other models and scenarios pre-
sented here. This is a result of comparing the impact of
vaccination on a different number of serotypes. In particular,
reduction in carriage prevalence of, for example, serotype ‘1’
as a result of vaccination in the high transmission scenario
steadily declines with increasing valency in M_F (figure 2).
However, the indirect effect of vaccination against serotypes
of lower prevalence is greater and hence comparing the
impact of vaccination on all vaccine serotypes includes both
the counteracting trends. Only in the high transmission setting,
inM_F is a net increase in vaccine effects against VTs predicted
for low valency vaccines.
While the models agree well on the qualitative relation
between vaccine valency and the herd immunity threshold,
we have observed stark differences in the quantitative results.
For example, M_CL predicted that much lower effective cover-
age is required for elimination of VT carriage. Many factors
contribute to this observation and some could be addressed
bymore detailed harmonization of the models to a specific set-
ting. However, two intrinsic model assumptions likely drive
this behaviour: (i) the strength of vaccine protection and
(ii) the strength of serotype competition. M_CL assumes a
relatively strong vaccine protection by reducing susceptibility
to VT acquisition permanently after vaccination. M_F assumes
vaccine protection, albeit non-leaky, to only hold for 10 years,
while M_B also assumes lifelong protection from vaccination,
although modelled as all-or-nothing and hence even stronger
than in M_CL. While the evidence suggests PCVs to be leaky
[50], little is known about upcoming pan-valent vaccines.
Vaccine protection has been found to remain present 5 years
after completion after childhood immunization [51], but there
is some evidence that protection declines over time albeit
with a half-life that exceeds 5 years [41]. Further, M_CL has
the weakest serotype competition of the models by assuming
leaky protection against heterologous acquisition of additional
colonizing strains during carriage with the most competitive
serotypes providing stronger protection against new acqui-
sition. In comparison, M_B and M_F, respectively, assume
competitive exclusion on acquisition and potential co-infection
but only after non-leaky heterologous immunity following
rsif.royalsocietypublishing.org
8acquisition has ended. With the relatively weak competition of
serotypes inM_CL, a targeted paediatric carriage prevalence is
achieved with lower transmission intensity. This in turn will
ease elimination of vaccine serotypes in comparison to the
other models where transmission is more intense. Recent
advances in molecular serotyping methods have shown
the pneumococci frequently co-colonize [52,53]. While
epidemiological studies suggest that carriage induces both
homologous and heterologous protection such protection from
a single episode of carriage likely is relatively weak [25,54,55].J.R.Soc.Interface
14:201706205. Conclusion
Using three different modelling approaches for pneumococcal
ecology that represent a range of alternative assumptions on
pneumococcal immunity and serotype competition, we
found that NVT competition helps vaccines of limited valen-
cies eliminate VT carriage. This implies that new vaccines
that targeted the majority of pneumococcal serotypes will
benefit less from NVT competition and are likely to offerless indirect protection than current PCVs. Head-to-head com-
parison of current PCVswith high-valency vaccines should not
only be on the grounds of non-inferiority of direct effects but
should also account for indirect effects, and closely monitor
IPD endpoints.Data accessibility. All data generated or analysed during this study are
included in this article and its electronic supplementary material.
The model code is available from the authors on reasonable request.
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